Low Dose Magnesium Sulphate Versus Standard Pritchard Regimen In Management Of Severe Preeclampsia/Eclampsia

• Status: Completed
• Trial end date: 2018-01-22
• Target enrollment: 0
• Participant gender: Female

Summary

Background - Preeclampsia/eclampsia, a pregnancy specific multi-systemic disease, is associated with considerable maternal and perinatal morbidity and mortality. Prevention and/or treatment of convulsion with magnesium sulphate, among others, is life-saving. Despite different regimens that have been tried, the minimum effective dose of MgSO4 for the prevention of eclampsia in patients with preeclampsia and treatment of convulsion in those with eclampsia has not been determined.

Objectives - To compare the maternal and perinatal outcomes and maternal side effects in eclamptic and preeclamptic participants treated with low dose regimen of MgSO4 with those treated with the Pritchard regimen.

Materials and Methods - This will be a prospective, single blinded randomized controlled study of low dose versus Pritchard regimens of MgSO4. Participants will be randomly assigned to the either arm of the study. Efficacy and adverse effects of the drug on the mother and baby will be noted. Data will be collated, tabulated and then statistically analysed using the statistical package for social sciences (SPSS) Results - Conclusion will be drawn and recommendation made from the findings in the study.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Adebayo Joshua Adeniyi
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

• Pregnant women with diagnosis of severe preeclampsia/eclampsia

Exclusion Criteria:

• Administration of MgSO4 before admission.

• Administration of diazepam or phenytoin before admission

• Maternal complications such as disseminated intravascular coagulation, cerebrovascular accident, renal disease, HELLP syndrome and aspiration pneumonitis.

• Multiple gestation

• Gestational ages below 28 weeks

• Postpartum eclampsia